Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
A phase 2 trial of SKB264 in ovarian cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
Overview
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC is a phase 2 interventional study registered as NCT07341100 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 20 participants enrolled, started 2026-01-16 and due to reach its primary completion in 2028-01. Interventions recorded: SKB264 and Clarithromycin.
Similar pages
not linked directly; found by shared links- TrialSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Study of KL590586 in Patients With Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Study of SKB571 in Patients With Lung Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB103 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB565 for Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB118 Injection in Advanced Solid Tumors
Shares Sichuan Kelun-Biotech and the tag pipeline.
- TrialSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Sichuan Kelun-Biotech and the tag pipeline.